CBAY / CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

The leading drug candidate in the biotech's pipeline scored another win. Seladelpar's existing Breakthrough Therapy Designation was expanded by the FD more_horizontal

CymaBay Therapeutics stock is continuing a slide that began last week. The pullback came on the heels of the biotech's dilution-causing stock and warr more_horizontal

NEWARK, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therap more_horizontal

The biotech upsized its planned share issue. It's now seeking to raise gross proceeds of $225 million; previously, it was aiming for $150 million. more_horizontal

The biotech is going to the well for more capital. It is seeking to raise $150 million in a share-and-warrant flotation. more_horizontal

Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive re more_horizontal

CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up. more_horizontal